Incorporating biomarker testing is key to optimizing outcomes in HR+/HER2- breast cancer, especially in recurrent and hormone-refractory disease. Be sure your team is prepared to apply the latest evidence ranging from pearls for biomarker testing to considerations for appropriate treatment sequencing. Gain important insights from leading breast cancer experts in Part 6 of our Breast Cancer Hot Topics series, including:tips for leveraging biomarker testing to individualize care and improve outcomes in HR+/HER2- breast cancer review emerging evidence in HR+/HER2- breast cancer solve challenging real-world cases. This activity is delivered in partnership with After Breast Cancer Diagnosis (ABCD).
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/novel-emerging-treatments-hr-her2-breast-cancer
- Start Date: 2024-10-25 05:00:00
- End Date: 2024-10-25 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.25 hours
AMA PRA Category 1 Credit™️: 1.25 hours
Nursing: 1.25 hours
Pharmacy: 1.25 hours - MOC Credit Details: ABIM - 1.25 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 11250.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 11250.0 - Is Kind Support: False Source: Gilead Sciences, Inc. - Amount: 8291.67 - Is Kind Support: False Source: Merck (Any division) - Amount: 8333.33 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology
Subscribe
Login
0 Comments
Oldest